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simak.ali@imperial.ac.ukAbstractThe development and growth of prostate cancer is dependent on androgens; thus, the
identification of androgen-regulated genes in prostate cancer cells is vital for defining
the mechanisms of prostate cancer development and progression and developing new
markers and targets for prostate cancer treatment. Glycine N-methyltransferase (GNMT)
is a S-adenosylmethionine-dependent methyltransferase that has been recently identified
as a novel androgen-regulated gene in prostate cancer cells. Although the importance of
this protein in prostate cancer progression has been extensively addressed, little is known
about the mechanism of its androgen regulation. Here, we show that GNMT expression is
stimulated by androgen in androgen receptor (AR) expressing cells and that the stimulation
occurs at the mRNA and protein levels. We have identified an androgen response element
within the first exon of the GNMT gene and demonstrated that AR binds to this element
in vitro and in vivo. Together, these studies identify GNMTas a direct transcriptional target of
the AR. As this is an evolutionarily conserved regulatory element, this highlights androgen
regulation as an important feature of GNMT regulation.Key Words
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(2013) 51, 301–312IntroductionAndrogens play a central role in the biology of normal
prostate development and prostate cancer progression
(Shen & Abate-Shen 2010). These hormones mediate
their effects through the action of the androgen receptor
(AR), a member of the nuclear receptor superfamily of
ligand-activated transcription factors (Brinkmann et al.
1999, Lu et al. 2006, Dehm & Tindall 2007). Following
androgen binding, AR dissociates from heat-shock proteins
and translocates to the nucleus where it binds to androgen
response elements (AREs) of target genes in associationwith coactivators and corepressors to regulate gene
expression (Shang et al. 2002, Heemers & Tindall 2007).
Previous studies have extensively shown that transcrip-
tional regulation by AR drives prostatic differentiation
during development (Cunha et al. 2004) and oncogenic
transformation during cancer (Heinlein & Chang 2004,
Lamont & Tindall 2011). Therefore, the mainstay treat-
ment for non-organ confined prostate cancer has been
directed at suppressing AR activity through androgen dep-
rivation therapies. However, although initially effective,sed under a Creative Commons
nported License.
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the tumours progress to a castration-resistant form, for
which few therapeutic options are available. Importantly,
accumulated evidence suggests that castration-resistant
prostate cancer (CRPC) remain dependent on the
expression and transcriptional activity of the AR (Feldman
& Feldman 2001, Gregory et al. 2001, Chen et al. 2004,
Balk & Knudsen 2008, Waltering et al. 2009). Downstream
targets of the AR are therefore of great importance for
further characterising the disease and thus developing new
markers and therapy targets for prostate cancer treatment.
Glycine N-methyltransferase (GNMT) is a tetrameric
multifunctional protein that plays an important role in
the methionine and one-carbon metabolism by acting as
both a methyltransferase enzyme and a folate-binding
protein (Blumenstein & Williams 1960, Cook & Wagner
1984). As a methyltransferase, GNMT catalyses the
transfer of a methyl group from S-adenosylmethionine to
glycine to form S-adenosylhomocysteine and sarcosine
(N-methylglycine). In recent years, increasing attention
has been paid to the role of GNMT in prostate cancer since
the discovery that sarcosine, the metabolite generated
by GNMT, was highly elevated during prostate cancer
progression to metastasis and, importantly, that it could
be detected noninvasively in urine (Sreekumar et al. 2009).
By its function ingenerating sarcosine, GNMT was predicted
to play a critical role in modulating prostate cancer
invasion. Indeed, Sreekumar et al. showed that GNMT
knockdown resulted in a significant reduction in prostate
cancer cell invasion. In addition, experiments carried out in
prostate cancer cell lines revealed that androgen treatment
up-regulates GNMT expression and that the AR directly
binds to the GNMT promoter (Sreekumar et al. 2009).
We have previously characterised the androgen-
regulated gene expression in LNCaP cells by microarray
analysis andfoundthatGNMTwassignificantlyup-regulated
following androgen treatment (Ngan et al. 2009). Later
studies have further explored the role of this
protein in prostate cancer (Song et al. 2011, Khan et al.
2013);however, theandrogenregulationofGNMTremained
largely unexplored. In light of the important role of this
protein in prostate cancer progression, we aimed to charac-
terise further the mechanism of GNMT androgen regulation.Materials and methods
Reagents
The synthetic androgen methyltrienolone (R1881) was pur-
chased from Perkin Elmer Life Sciences (Beaconsfield, UK)http://jme.endocrinology-journals.org
DOI: 10.1530/JME-13-0169
 2013 The authors
Printed in Great Britainand was dissolved in 100% ethanol at a stock concentration
of 100 mM and stored atK20 8C. A working concentration
of 10 mM was prepared and was added to cells at a final
concentration of 1 nM, unless otherwise stated.Cell culture
The cell lines used were obtained from the American
Type Culture Collection except BPH-1 obtained from
Dr Charlotte Bevan (Imperial College, London, UK)
and LNCaP-C4 and LNCaP-C4-2B cells obtained from
Dr Hayley Whitaker (Cambridge Research Institute,
Cambridge, UK). All cell lines were verified by short-
tandem repeat profiling (LGC Standards, Teddington, UK)
used within 30 passages of the original, source passage and
tested every 3 months to ensure mycoplasma negativity
(MycoAlert, Lonza, UK).
LNCaP, LNCaP-C4, LNCaP-C4-2B, BPH-1, Du145 and
PC-3 cells were maintained at 37 8C, 5% CO2 in RPMI-1640
medium (Sigma–Aldrich) with 10% FCS (First Link,
Birmingham, UK). T47D and COS-1 cells were maintained
in DMEM medium (Sigma–Aldrich) with 10% FCS.
RWPE-1 cells were maintained in keratinocyte serum-free
medium supplemented with bovine pituitary extract and
recombinant epidermal growth factor (Gibco-Invitrogen
Corporation). Seventy-two hours before exposure to
androgen, media were replaced with phenol red-free
RPMI (or DMEM) (Gibco-Invitrogen Corporation) supple-
mented with 10% dextran-coated charcoal-treated serum
(DSS; First Link). All media were supplemented with
2 mM L-glutamine, 100 U/ml penicillin and 100 mg/ml
streptomycin (Sigma–Aldrich).Plasmids
The Renilla luciferase vector was pRL-TK (Promega).
AR expression and control vectors (pSG5-AR and pSG5)
were gifts from Dr Charlotte Bevan.
To generate the GNMT promoter vector, a 1.45 kb
GNMT promoter region was amplified from LNCaP
genomic DNA using the LongRange PCR kit (Qiagen Ltd)
(forward 5 0-ATCTCAGGGGATGGA-3 0, reverse 5 0-AAG-
CAGCCATGCCTT-3 0). The PCR product was amplified
once again using the LongRange PCR kit with the
addition of BglII and HindIII restriction sites (forward
5 0-GCTAGGAGATCTCGCGAGAGCGGCCCTGTAATTG-
AGCAGAAAGG-3 0, reverse 5 0-CTAGCCAAGCTTCCGCC-
ACCCCCAGGGAGCGGGTCCGGTAC-3 0). Both the PCR
product and the pGL3-basic vector (Promega) werePublished by Bioscientifica Ltd
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ligation and subsequently verified by sequencing.
The GNMT promoter ARE mutants were generated by
site-directed mutagenesis of the GNMT promoter reporter
wild-type vector using the QuikChange Multi-site-directed
Mutagenesis kit (Agilent Technologies, Stockport, UK).
Mutagenic oligonucleotides were designed such that the
ARE consensus sequences were abolished by the insertion
of a restriction site for the enzyme MluI. The sequences
are given in Supplementary Table 1, see section on
supplementary data given at the end of this article.siRNA transfections
Cells were transfected with control siRNA (Negative
control N.2, Ambion, Applied Biosystems) or siRNA
specific to AR (s1539, Ambion, Applied Biosystems) using
Lipofectamine RNAiMAX (Invitrogen) according to the
manufacturer’s protocols. LNCaP cells were seeded in
10 cm dishes at a density of 2!106 in 10 ml phenol red-
free RPMI supplemented with 10% DSS without anti-
biotics for 24 h. On the day of transfection, the siRNA
transfection reagent complex was prepared by diluting
600 pmol siRNA. This was followed by the addition of
Lipofectamine RNAiMAX, mixed gently and incubated for
20 min at room temperature. The siRNA-Lipofectamine
complexes were added drop-wise to the cells. Cells were
gently mixed and incubated for 24 h, following which100
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Figure 1
Androgen up-regulates the expression of GNMT mRNA and protein in a
time-dependent manner. TaqMan RT-PCR for GNMT (A), PSA (B), NDRG1 (C)
and TMPRSS2 (D) was performed from RNA prepared from LNCaP cells
cultured in RPMI lacking phenol red supplemented with 10% DSS for 72 h
followed by the addition of either ethanol or 1 nM R1881 for 24, 48 and
72 h. Data were normalised to GAPDH levels. The expression of each gene
in cells treated with ethanol for 24 h was set to one, with the expression
level in the other conditions being shown relative to this. Results are shown
as mean values of three replicates with error bars showing S.E.M. (E) LNCaP
http://jme.endocrinology-journals.org
DOI: 10.1530/JME-13-0169
 2013 The authors
Printed in Great Britainfresh phenol red-free RPMI supplemented with 10% DSS
and 1 nM R1881 was added. Cells were incubated for
48 h before harvesting for RNA or protein extraction.Real-time quantitative PCR
Cells were treated for the indicated times and RNA
harvested using RNeasy mini preparation kit (Qiagen
Ltd) according to the manufacturer’s instructions. Prior
to elution, columns were treated with DNase using
the RNase-Free DNase Set (Qiagen Ltd) to remove any
residual DNA. Two micrograms of RNA were used for RT
reaction using RevertAid M-MuLV Reverse Transcriptase
(Fermentas, York, UK). The obtained cDNA was then
diluted 1:10 and 2 ml cDNA subsequently used as a
template for each PCR. TaqMan real-time RT-PCR was
carried out according to the manufacturer’s instructions
on an Applied Biosystems 7500 fast Real-time PCR system
using Assay-on Demand primers (Applied Biosystems).
The assay identification numbers are given in Supple-
mentary Table 2, see section on supplementary data given
at the end of this article.Western blotting
Whole cell lysates were prepared in RIPA buffer
(Sigma–Aldrich) containing complete protease inhibitors
(PIs; Roche Diagnostics Ltd) and protein concentrationE
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cells were treated for the indicated times, whole cell lysates were separated
by SDS–PAGE and immunoblotted for GNMT and b-actin. The polypeptide
corresponding to GNMT is arrowed and molecular weight markers are
expressed in kDa. (F) Immunofluorescence staining of GNMTwas
performed in LNCaP cells treated for 48 h. The GNMT antibody was
detected with Alexa Fluor 488-labelled secondary and TO-PRO-3 was used
for counterstaining of nuclei. All images were acquired using a Zeiss
LSM510 confocal microscope. Scale barZ10 mm.
Published by Bioscientifica Ltd
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(Thermo Fisher Scientific UK Ltd, Leicestershire, UK).
Twenty micrograms of proteins were separated on a 12%
SDS–polyacrylamide gel and transferred onto a nitrocellu-
lose membrane for immunodetection, using the iBlot
7-Minute Blotting System (Invitrogen). The membrane
was then blocked in PBS-0.1% Tween (v/v) (PBST)
containing 5% (w/v) dried skimmed milk powder followed
by overnight incubation at 4 8C with gentle shaking with
primary antibody against: GNMT (HPA027501, Sigma–
Aldrich), AR (Sc-816, Santa Cruz Biotechnologies) and
b-actin (ab6276, Abcam Ltd, Cambridge, UK). The
membrane was washed three times in PBST and incubated
with the appropriate HRP-conjugated secondary antibody
(Dako, Ely, UK) for 90 min at room temperature. The
membrane was washed again three times in PBST. The
SuperSignal West Pico Chemiluminescent Substrate
(Perbio Science, Cramlington, UK) was added to the
membrane followed by autoradiography using Hyperfilm
ECL (GE Healthcare, Chalfont St Giles, UK).24 h 48 h 72 h 24 h 48 h 72 h
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LNCaP cells grown on glass coverslips were fixed in 4%
paraformaldehyde for 10 min at room temperature. Cells
were then washed with PBS twice and 0.5 M glycine
solution was added for 20 min to quench aldehyde-
induced autofluorescence. After washing, cells were
permeabilised in 0.3% (v/v) Triton X-100 for 10 min.
Coverslips were blocked with 1% (w/v) BSA and 2% FCS
(v/v) for 30 min following incubation with the appro-
priate primary antibody for 1 h at room temperature.
Cells were then washed with PBS twice and incubated in
the dark for 1 h at room temperature with the secondary
antibody Alexa Fluor 488 (Invitrogen). Finally, counter-
staining of nuclei was performed using TO-PRO-3
(Invitrogen) for 5 min. The cells were washed again
three times and mounted in Vectashield Mounting
Medium H-1000 (Vector Laboratories, Southgate, UK).
Images were acquired with a Zeiss LSM 510 META
confocal microscope fitted with an LSM 510 META
scanhead and driven by Zeiss LSM 510 confocal software
using a Plan-Apochromat 63! (1.40 numerical aperture,
oil) lens and Immersol 518F oil (Carl Zeiss Ltd,
Hertfordshire, UK).Figure 2
GNMT is androgen up-regulated in AR-positive cell lines. TaqMan RT-PCR
for GNMT (A), PSA (B), NDRG1 (C) and TMPRSS2 (D) was performed using
RNA prepared from LNCaP-derived lines C4 and C4-2B. Cells were cultured
and treated using the same conditions described for LNCaP cells in Fig. 1.Reporter gene assays
LNCaP cells were seeded in 24-well plates at a density
of 70 000 cells/well phenol red-free RPMI mediumhttp://jme.endocrinology-journals.org
DOI: 10.1530/JME-13-0169
 2013 The authors
Printed in Great Britainsupplemented with 10% DSS. Forty-eight hours later,
the cell medium was replaced with fresh RPMI phenol
red-free medium supplemented with 10% DSS with or
without 1 nM R1881. Each well was transfected with
500 ng DNA, consisting of: 100 ng of firefly luciferase
pGL3 vectors, 100 ng Renilla luciferase vector (pRL-TK)
and 300 ng Bluescribe plasmid DNA as carrier DNA.
Cells were transfected using Lipofectamine LTX and
PLUS Reagent (Invitrogen) according to the manu-
facturer’s instructions. Twenty-four hours following
transfection, firefly and Renilla luciferase activities were
determined using the Dual-Glo Luciferase Assay System
(Promega). Firefly luciferase readings were subsequentlyPublished by Bioscientifica Ltd
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the Renilla luciferase activity served to control for
transfection efficiency.B
C
D
1.0
0.5
0.0
R1881 R1881
siARsiControl
siARsiControl
Ethanol
R1881 R1881
siARsiControl
Ethanol
R1881
130
95
36
36
1.4
1.2
1.0
0.8
0.6
0.4
0.2
0
28
55
R1881
AR
GNMT
β-actin
Ethanol
Fo
ld
 in
du
Fo
ld
 in
du
ct
io
n
R1881
NDRG1
PSA
R1881
siARsiControl
Ethanol
1.2
1.0
0.8
0.6
0.4
0.2
0
Fo
ld
 in
du
ct
io
n
Figure 3
AR knockdown suppresses the androgen-induced GNMT gene. (A) LNCaP
cells were cultured in RPMI containing 10%DSS in the absence of antibiotics
for 24 h. Cells were then transfected with siRNAs targeting AR or control.Electrophoretic mobility shift assay
COS-1 cells were seeded in 10 cm dishes at a density of
1!106 in 10 ml DMEM containing 10% FCS without
antibiotics. Following overnight incubation, cell medium
was replaced with fresh DMEM containing 10% FCS
without antibiotics. Cells were transfected using Lipofect-
amine LTX and PLUS Reagent with 2 mg pSG5 or pSG5-AR
expression vectors. Twenty-four hours after transfection,
cells were treated with 10 nM R1881 for 1 h. Cells were
then washed twice with ice-cold PBS and harvested by
scraping in ice-cold PBS buffer containing PIs. Cells were
centrifuged at 10 000 g for 10 min at 4 8C and the pellet
re-suspended in high-salt buffer (HSB: 400 mM KCl;
20 mM Tris–HCl, pH 7.5; 2 mM dithiothreitol and 20%
glycerol (v/v)) supplemented with PIs. Cells were frozen
at K80 8C and thawed on ice three times and then
centrifuged for 15 min at 4 8C. The supernatant was stored
in aliquots at K80 8C. The double-stranded oligonucleo-
tides containing the ARE sequences are given in Supple-
mentary Table 3, see section on supplementary data given
at the end of this article. The oligos were purchased as
single strands, one labelled with the infrared IR-800 dye
and the other unlabelled (Eurofins, Ebersberg, Germany).
Hybridisation of the oligos was performed by mixing 1 mM
labelled oligo with 1 mM unlabelled oligo. The mix was
placed in boiling water, which was allowed to cool at room
temperature overnight. For electrophoretic mobility shift
assay (EMSA), 2.5 ml COS-1 HSB extract were pre-incubated
with 142 ng/ml poly(deoxyinosine-deoxycytosine) (dI.dC)
for 30 min at 4 8C. For supershift, 2 mg AR antibody
(sc-816X, ChIP-grade; Santa Cruz Biotechnologies) was
added. The hybridised oligos (0.1 mM) were then added
followed by incubation for 4 h at 4 8C. The bound probe
was separated from unbound probe by gel electrophoresis
in a 4% polyacrylamide gel at 100 V for 1 h at 4 8C. The
infrared signal was visualised using the Odyssey (LI-COR)
IR imaging system.
Twenty-four hours after transfection, cells were treated with 1 nM R1881
with an equal volume of ethanol being added to the vehicle control. RNA
was prepared after a further 48 h and TaqMan RT-PCR forAR andGNMTwas
performed. Data have been normalised to GAPDH levels and AR or GNMT
expression levels in the siRNA control treated with R1881 was set to one.
Results are shown as mean values of three independent experiments
performed in triplicates with error bars representing S.E.M. (B) LNCaP cells
were transfectedwith siRNAs as for A.Whole cell lysates were prepared and
immunoblotted for AR, GNMT (arrowed) and b-actin. Molecular weight
markers are expressed in kDa. Suppression of the androgen-regulated
genes PSA (C) and NDRG1 (D) following silencing of AR is also shown.Chromatin immunoprecipitation
LNCaP cells were cultured in RPMI medium lacking
phenol red supplemented with 10% DSS for 72 h followed
by addition of 10 nM R1881 or ethanol for 1 h. Cells were
then cross-linked with 1% formaldehyde (Sigma–Aldrich)
for 10 min at room temperature and washed three timeshttp://jme.endocrinology-journals.org
DOI: 10.1530/JME-13-0169
 2013 The authors
Printed in Great Britain
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in PBS with PIs and lysed in lysis buffer (1% SDS, 10 mM
EDTA and 50 mM Tris–HCl, pH 8.0) containing PIs for
10 min on ice (200 ml lysis buffer/1!106 cells). Cells were
sonicated for 10 min at 4 8C using 20-s high-power pulses
and then centrifuged at 10 000 g for 10 min at 4 8C. 1.8 ml
dilution buffer (1% Triton X-100, 2 mM EDTA, 20 mM
Tris–HCl, pH 8.0, and 150 mM NaCl) was added for 200 ml
sonicated lysate. Fifty microliters of sonicated lysate were
used as the input sample and the rest was used for
immunoprecipitation. Dynabeads protein A (for rabbit
IgG1) (Invitrogen) were washed three times with blocking
solution (0.5% (w/v) BSA in PBS) and then added to the
sonicated lysates for 30 min at 4 8C on rotation. Two
micrograms of AR antibody (sc-816X, ChIP-grade; Santa
Cruz Biotechnologies) or rabbit IgG were added and
incubated overnight at 4 8C on rotation. Preblocked
dynabeads were then added and incubated for 1 h at 4 8C
on rotation. The supernatant was removed and sequen-
tially the following buffers were added for 5 min on
rotation at 4 8C: i) low-salt wash (0.1% SDS, 1% Triton
X-100, 2 mM EDTA, 20 mM Tris–HCl, pH 8.0, and 150 mM
NaCl)CPIs; ii) high-salt wash (0.1% SDS, 1% Triton X-100,
2 mM EDTA, 20 mM Tris–HCl, pH 8.0, and 500 mM
NaCl)CPIs; iii) LiCl wash (0.25 M LiCl, 1% NP40, 1%
sodium deoxycholate, 1 mM EDTA and 10 mM Tris–HCl,
pH 8.0)C PIs; and iv) Tris–EDTA wash (10 mM Tris–HCl
and 1 mM Na EDTA, pH 8.0). Finally, elution buffer
(1% (w/v) SDS, 10 mM NaHCO3) was added for 15 minA
–1223 +69 GNMTp 
+69 GNMTp 
+69 GNMTp 
+69 GNMTp 
–1223
–1223
–1223
Figure 4
Site-directed mutagenesis analysis of the three predicted AREs. (A) The
wild-type GNMT promoter reporter construct was generated by cloning
a 1.2 kb region of the GNMT gene into a pGL3-basic luciferase vector.
This construct was used as a template for site-directed mutagenesis of
ARE-I (ARE-I*), ARE-II (ARE-II*) and ARE-III (ARE-III*). The mutants were
generated by replacing part of the ARE sequence with the MluI restriction
site sequence (5 0-acggct-3 0). (B) The activity of the GNMT ARE mutants was
http://jme.endocrinology-journals.org
DOI: 10.1530/JME-13-0169
 2013 The authors
Printed in Great Britainon a shaker at room temperature and 5 M NaCl was added.
Reverse cross-linking was performed at 65 8C overnight.
0.5 M EDTA, 1 M Tris–HCl (pH 6.5) and proteinase K were
added to each sample and the tubes were then incubated
at 45 8C for 1 h. Immunoprecipitated DNA was recovered
by phenol/chloroform extraction and quantitative real-
time PCR was used to quantify recruitment of AR on PSA
and GNMT promoters. Primers were designed at either side
of the PSA enhancer or negative control region and the
GNMT ARE. Primer sequences are given in Supplementary
Table 4, see section on supplementary data given at the
end of this article.Results
GNMT is up-regulated by androgen treatment in
AR-positive cancer cells
We first examined the mRNA expression of GNMT in the
LNCaP, AR-positive prostate cancer cell line, which is
dependent on androgens for growth. LNCaP cells were
maintained in steroid-depleted medium for 72 h and then
treated with either ethanol or the synthetic androgen
R1881 for 24, 48 and 72 h. GNMT expression was then
quantified by TaqMan real-time RT-PCR (Fig. 1A). The
GNMT transcript was stimulated by R1881 in a time-
dependent manner, such that a 26-fold increase was
detected 24 h after treatment and reached w80-fold at
72 h. As a control, expression of the well-knownB
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evaluated and up-regulation of their transcripts following
androgen treatment was confirmed (Fig. 1B, C, and D).
In addition, androgen-dependent up-regulation of
GNMT in LNCaP cells was also shown at a protein level,
as demonstrated by western blotting (Fig. 1E) and
immunofluorescent staining (Fig. 1F).
To exclude the possibility that GNMT androgen
regulation was unique to LNCaP cells, its expression was
evaluated in two additional AR-positive cell lines, the
hormone-insensitive LNCaP-derived prostate cancer cell
lines C4 and C4-2B. Indeed, all cell lines showed androgen
regulation of GNMT (Fig. 2A) and demonstrated increasing
expression of the known androgen-regulated genes PSA,
NDRG1 and TMPRSS2 upon R1881 treatment (Fig. 2B, C,
and D). In addition, GNMT expression was evaluated in a
broader panel of prostate cell lines (Supplementary
Figure 1, see section on supplementary data given at the
end of this article). The benign prostate epithelial RWPE-1
cell line, the benign prostatic hyperplasia-derived cell
line BPH-1, as well as DU145 and PC-3 cell lines showed
low or undetectable levels for AR and low levels of GNMT.
It was therefore clear that the expression of GNMT was
limited to prostate lines expressing high levels of AR.P
Figure 5
EMSA shows that AR binds to the ARE located within exon 1 of the GNMT
gene. (A) COS-1 cells cultured in DMEM containing 10% FCS in the absence
of antibiotics were transiently transfected with pSG5 control vector or
AR expression plasmids. Twenty-four hours after transfection, cells were
treated for 1 h with 10 nM R1881. High-salt buffer (HSB) cell extracts were
prepared as described in the Materials and methods section. AR expression
was confirmed bywestern blotting. (B)HSBcell extractswerefirst incubated
with poly(dI.dC), in the absence or presence of an AR antibody, followed
by incubation with the IR-800-labelled double-stranded oligonucleotides.
The extract–oligonucleotide mix was resolved by electrophoresis through
a 4% polyacrylamide gel and migration of the oligonucleotides through
the gel was determined using the Odyssey (LI-COR) IR imaging system.
Arrows indicate the positions of the unbound (P), shifted (S) and the
antibody-AR-oligonucleotide ‘supershifted’ (SS) probe.AR knockdown inhibits GNMT expression in LNCaP cells
To determine whether the androgen regulation of GNMT
was mediated by AR, we performed RNA interference of AR
in LNCaP cells. LNCaP cells were maintained in steroid-
depleted medium for 24 h and subsequently transfected
with control and AR-specific siRNAs. Twenty-four hours
after transfection, 1 nM R1881 or ethanol was added for a
further 48 h and RNA and proteins were collected.
Interestingly, we found that AR knockdown significantly
suppressed GNMT mRNA (Fig. 3A) and protein levels
(Fig. 3B) in the presence of androgen, suggesting that
GNMT is a transcriptional target of AR. To confirm the
specificity of the siRNA targeting AR, we also showed the
repression of AR mRNA and protein upon knockdown.
Notably, we observed a significant reduction of AR mRNA
level upon R1881 treatment, which is in agreement with
the finding that AR mRNA expression shows a biphasic
regulation by androgen (Nirde et al. 1998) through two
AREs in exon 5 of the AR gene (Dai & Burnstein 1996).
As a control, we demonstrated reduction of the well-
known androgen-regulated genes PSA (Fig. 3C) and
NDRG1 (Fig. 3D) following silencing of AR. Taken
together, these results show that GNMT androgen
up-regulation is mediated by AR.http://jme.endocrinology-journals.org
DOI: 10.1530/JME-13-0169
 2013 The authors
Printed in Great BritainIdentification of an ARE in exon 1 of the GNMT gene
As GNMT expression is highly responsive to R1881, we
hypothesised that AR was directly regulating its expression.
By carrying out a bioinformatic analysis for steroid
hormone response elements using the web-based tool
Mulan (http://mulan.dcode.org/) (Ovcharenko et al. 2005),
three putative AREs were identified proximal to the gene
promoter region: ARE-I and ARE-II at position K1111/
K1097 and K716/K708 respectively, and ARE-III atPublished by Bioscientifica Ltd
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AR is recruited to the GNMT ARE in an androgen-dependent manner.
(A) Diagramatic representation of the PSA (top) and GNMT (bottom)
promoter regions. AREs are highlighted in boxes and arrows indicate the
location of PCR primer pairs. (B) LNCaP cells were cultured in RPMI medium
lacking phenol red supplemented with 10% DSS for 72 h followed by
addition of 10 nM R1881 or ethanol for 1 h. Cells were then cross-linked,
lysed and sonicated. Immunoprecipitations were performed using an
antibody specific for AR or rabbit IgG. Immunoprecipitated DNA was
reverse cross-linked and recovered by phenol/chloroform extraction.
Real-time PCR was carried out using primers for the regions indicated in
part A. The PSA enhancer region was chosen as a positive control, and a
region distant from ARE elements as a negative control. Results show the
mean values obtained from ChIP analysis of two replicates.
Figure 7
Nucleotide sequences of the region flanking the GNMT ARE in multiple
species are shown. The box demarks the region of ARE homology and the
translation start site is underlined. Sequences were retrieved from the UCSC
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on supplementary data given at the end of this article).
The position of the start site at the 14th base upstream
the ATG codon was identified by Lee et al. (2009) and
confirmed by 5 0 RACE analysis of androgen-treated LNCaP
mRNA (data not shown).
To investigate the function of these AREs, we carried
out a gene promoter analysis. In brief, a region of theGNMT
gene that includes the three putative AREs was amplified by
PCR from LNCaP genomic DNA and cloned into the pGL3-
basic reporter vector, upstream of the promoter-less firefly
luciferase gene (GNMTp). In addition, we generated
reporter constructs containing mutations in the three
AREs by site-directed mutagenesis (Fig. 4A). The androgen
responsiveness of the wild-type and mutated GNMT
promoter constructs was determined by luciferase reporter
assays. LNCaP cells were transiently transfected with the
luciferase constructs in the absence or presence of
androgen. The wild-typeGNMT reporter constructs showed
stimulation of the luciferase gene upon R1881 treatment of
approximately 2-fold. Mutation of ARE-I and -II did not
show a decrease in androgen responsiveness, whereas
mutation of ARE-III resulted in an ablation of androgen-
inducible luciferase activity, indicating that AR directly
regulates GNMT expression through this ARE (Fig. 4B).
(http://genome.ucsc.edu) using the following genome builds: hg19
(human), mm10 (mouse), rn5 (rat), oryCun2 (rabbit), anoCar2 (lizard),
xenTro3 (xenopus) and danRer7 (zebrafish). Multiple-sequence alignment
was performed using Clustal Omega (http://www.ebi.ac.uk/Tools/msa/
clustalo/). Any nucleotide change from the human sequence is in bold and
underlined. ‘*’ indicates positions that have a single, fully conserved
residue; ’.’ indicates conservation between groups of weakly similar
properties (scoring%0.5 in the Gonnet PAM 250 matrix).AR binds to the GNMT ARE in an androgen-dependent
manner in vitro and in vivo
We then assessed whether AR was able to bind to this
sequence in vitro by performing EMSA. The sequence of thehttp://jme.endocrinology-journals.org
DOI: 10.1530/JME-13-0169
 2013 The authors
Printed in Great Britainwild-type and mutant GNMT AREs together with the ARE-I
contained in the PSA promoter was synthesized as
oligonucleotides having the 5 0 end labelled with the
infrared IR-800 dye (Supplementary Table 3). The PSA
oligonucleotide sequence was chosen as positive control,
as it has been previously shown to specifically bind the AR
in EMSA assays (Luke & Coffey 1994). EMSA was
performed using cell extracts from COS-1 cells transfected
with either AR expression vector or pSG5 empty vector
(Fig. 5A) and revealed that the AR interacted with the
GNMT as well as the PSA AREs, both in the absence and
presence of an AR antibody, whereas no binding was
detected to the mutated GNMT ARE (Fig. 5B).Published by Bioscientifica Ltd
Table 1 Examples of genes encoding classical AREs
Gene Classical AREs (AGAACA nnn TGTTCT) Reference
MMTV AGAACA gtt TGTAAC Ham et al. (1988)
C3(1) AGAACA tca CGTACT Claessens et al. (1989)
PSA (ARE-I) AGAACA gca AGTGCT Lund et al. (1991)
PSA (ARE-III) GGAACA tat TGTATC Cleutjens et al. (1997)
GNMT TGGACA gcg TGTACC
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located within exon 1 of the GNMT gene, chromatin
immunoprecipitation (ChIP) assay was carried out. LNCaP
cells were maintained in steroid-depleted medium for 72 h
and subsequently treated with either ethanol or R1881.
ChIP was performed using AR antibody or rabbit IgG as a
control. AR binding was quantified by real-time PCR using
primer pairs surrounding the GNMT ARE as well as the
enhancer ARE element and a region to which AR does not
bind, within the PSA gene that provided a positive and
negative control respectively (Fig. 6A). The ChIP assay
revealed a ligand-dependent recruitment of AR to the
GNMT ARE (Fig. 6B).Discussion
In this study, we have characterised the expression and
the androgen regulation of GNMT and identified an
ARE in exon 1 of the GNMT gene. Sreekumar et al. (2009)
demonstrated that GNMT mRNA increased upon andro-
gen treatment in LNCaP and VCaP cell lines. In agreement
with these findings, we have shown that GNMT mRNA
and protein are strongly stimulated by the synthetic
androgen R1881 in the LNCaP cell line in a time-
dependent manner. Indeed, we have previously shown
that GNMT belongs to a cluster of genes (Cluster U4)
whose expression increases slowly over time upon R1881
treatment (Ngan et al. 2009). The androgen regulation of
GNMT was also confirmed in two additional AR-positive
cell lines, the hormone-insensitive LNCaP sublines C4
and C4-2B. Furthermore, we have shown that GNMT
stimulation of expression is indeed AR mediated, asTable 2 Examples of genes encoding AR-selective ARE
Gene Selective AREs (AGAACA n
PB AGTACT cca AGAACC
SC (enhancer) AGAACT ctg CGAACA
SC GGGACA cag CCTGCT
SLP AGAACT ggc TGACCA
http://jme.endocrinology-journals.org
DOI: 10.1530/JME-13-0169
 2013 The authors
Printed in Great Britainknockdown of AR resulted in a reduction in GNMT
mRNA and protein levels.
The strong stimulation of GNMT by androgen
together with the detection of its expression in AR-positive
cancer cell lines and its inhibition upon AR knockdown
indicated that AR may directly regulate GNMT expression.
As AR regulates transcription by binding to consensus
DNA sequences in the regulatory regions of its target genes
(Heinlein & Chang 2004), we searched for putative AREs in
the GNMT promoter region. This analysis resulted in the
identification of three predicted AREs: ARE-I and ARE-II,
located within the GNMT promoter, and ARE-III, located
within exon 1 of the GNMT gene. A 1.2 kb region of the
GNMT promoter provided androgen regulation to a
luciferase reporter gene. Mutation of ARE-I or ARE-II had
no effect on androgen regulation, whereas mutation of
ARE-III prevented androgen stimulation, demonstrating
that ARE-III is able to function as an ARE. In addition,
EMSA analysis showed that the AR can bind to this
sequence and ChIP analysis confirmed that AR is recruited
in an androgen-dependent manner to a region of the
GNMT gene encompassing ARE-III.
The presence of an ARE within the coding region of a
gene has also been described for other androgen-regulated
genes, including the rat cystatin-related protein (crp2) gene
(Devos et al. 1997) and the human secretory component
(SC) gene (Haelens et al. 1999, 2001). GNMT is a protein
that is highly conserved among mammalian species.
About 90% amino acid sequence similarity is observed
between human, rabbit, rat and pig GNMT proteins
(Ogawa et al. 1993, 1998). By performing multiple-
sequence alignment analysis, we found that the AREs
nn AGAACA) Reference
Rennie et al. (1993)
Verrijdt et al. (1999)
Haelens et al. (2001)
Verrijdt et al. (2002)
Published by Bioscientifica Ltd
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Research S OTTAVIANI and others Androgen regulation of GNMT 51 :3 310was fully conserved in mammalian species and highly
conserved in the vertebrate lineage, suggesting that this
response element may act as a functional ARE across
species throughout evolution (Fig. 7).
Recent advances in ChIP-based assays have enabled
the generation of comprehensive maps of transcription
factors binding across the entire genome. With the aim of
understanding the AR-regulated gene network in either
androgen dependent or CRPC, global AR binding events
have been mapped, initially using microarrays of gene
promoter regions (Massie et al. 2007) and later by genome-
tiled arrays (Wang et al. 2009) and massively parallel
sequencing (Lin et al. 2009, Sreekumar et al. 2009, Yu et al.
2010, Massie et al. 2011). Interestingly, the ChIP-seq assay
performed by Sreekumar et al. revealed that AR was
recruited to the GNMT proximal promoter in LNCaP and
VCaP cell lines. Even though the region is not clearly
annotated in the paper, it appears to include the GNMT
ARE identified in this study, consistent with our findings.
Having identified a functional ARE within the
GNMT gene, we wondered whether the response element
was an example of a so-called ‘classical’ ARE, recognised
by all class I receptors, or ‘selective’ ARE, recognised
mainly by the AR (Denayer et al. 2010). Based on the
sequence homology to other previously validated AREs,
we were able to classify the GNMT ARE as a ‘classical’ ARE
(Tables 1 and 2). Consequently, not only AR but also the
other class I hormone receptors, glucocorticoid receptor
(GR), progestogen receptor and mineralocorticoid
receptor, should recognise this sequence. It has previously
been shown that the glucocorticoid dexamethasone (DEX)
is able to activate GNMT in the rat liver and to stimulate
its expression in the rat hepatoma cell line H4IIE (Rowling
& Schalinske 2003). However, to date, no glucocorticoid
response elements (GREs) have been identified in this
promoter region (Lee et al. 2009). Therefore, we wondered
whether the GNMT ARE was also a binding site for GR in
ChIP-seq assays. Interestingly, the GR ChIP-seq performed
in the A549 lung epithelial carcinoma cell line treated
with DEX revealed GR binding in a region comprising the
transcription start site and first exon of the GNMT gene
(Reddy et al. 2009). On the basis of these observations,
we propose that the GNMT ARE identified in this study
could also act as a GRE. Further studies will certainly be
required to verify this hypothesis, the most obvious of
which would be to determine whether GR activates the
GNMT reporter genes we have described herein.
While we were preparing our manuscript, Lee et al.
(2013) have reported five predicted ARE motifs in the
coding region and main body of the human GNMT genehttp://jme.endocrinology-journals.org
DOI: 10.1530/JME-13-0169
 2013 The authors
Printed in Great Britainand concluded that the only functional ARE was the 5 0
most element, which corresponds to the conserved motif
we have also identified. In our studies, we have examined
three ARE-like motifs in the GNMT promoter region
and have concluded that the androgen regulation of
GNMT can be imparted by binding of AR to a ‘classical’
ARE located within exon 1 of the GNMT gene, 18 bases
downstream the GNMT gene transcription start site, and
overlapping the translation start site. Collectively, these
results show GNMT as a direct transcriptional target
of the AR in the androgen-dependent LNCaP cell line
and suggest that regulation through a highly conserved
ARE element is a feature of GNMT expression in the
vertebrate lineage.Supplementary data
This is linked to the online version of the paper at http://dx.doi.org/10.1530/
JME-13-0169.Declaration of interest
The authors declare that there is no conflict of interest that could be
perceived as prejudicing the impartiality of the research reported.Funding
This work was supported by grants from Prostate Cancer Charity
(PCC/110727) and Cancer Research UK (C37/A12011, C37/A9335). Open
Access publication was funded by Imperial College London.Acknowledgements
The authors are grateful for the members of the group for advice and
technical help. They also thank Dr Charlotte Bevan for the pSG5-AR plasmid
and the Joron Trust for continuous support.References
Balk SP & Knudsen KE 2008 AR, the cell cycle, and prostate cancer.
Nuclear Receptor Signaling 6 e001. (doi:10.1621/nrs.06001)
Blumenstein J & Williams GR 1960 The enzymic N-methylation of glycine.
Biochemical and Biophysical Research Communications 3 259–263.
(doi:10.1016/0006-291X(60)90235-7)
Brinkmann AO, Blok LJ, de Ruiter PE, Doesburg P, Steketee K, Berrevoets CA
& Trapman J 1999 Mechanisms of androgen receptor activation
and function. Journal of Steroid Biochemistry and Molecular Biology 69
307–313. (doi:10.1016/S0960-0760(99)00049-7)
Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG
& Sawyers CL 2004 Molecular determinants of resistance to anti-
androgen therapy. Nature Medicine 10 33–39. (doi:10.1038/nm972)
Claessens F, Celis L, Peeters B, Heyns W, Verhoeven G & Rombauts W 1989
Functional characterization of an androgen response element in the
first intron of the C3(1) gene of prostatic binding protein. Biochemical
and Biophysical Research Communications 164 833–840.Published by Bioscientifica Ltd
Jo
u
rn
a
l
o
f
M
o
le
cu
la
r
E
n
d
o
cr
in
o
lo
g
y
Research S OTTAVIANI and others Androgen regulation of GNMT 51 :3 311Cleutjens KB, van der Korput HA, van Eekelen CC, van Rooij HC, Faber PW
& Trapman J 1997 An androgen response element in a far upstream
enhancer region is essential for high, androgen-regulated activity of the
prostate-specific antigen promoter.Molecular Endocrinology 11 148–161.
Cook RJ & Wagner C 1984 Glycine N-methyltransferase is a folate binding
protein of rat liver cytosol. PNAS 81 3631–3634. (doi:10.1073/pnas.81.
12.3631)
Cunha GR, Ricke W, Thomson A, Marker PC, Risbridger G, Hayward SW,
Wang YZ, Donjacour AA & Kurita T 2004 Hormonal, cellular, and
molecular regulation of normal and neoplastic prostatic development.
Journal of Steroid Biochemistry and Molecular Biology 92 221–236.
(doi:10.1016/j.jsbmb.2004.10.017)
Dai JL & Burnstein KL 1996 Two androgen response elements in
the androgen receptor coding region are required for cell-specific
up-regulation of receptor messenger RNA. Molecular Endocrinology 10
1582–1594. (doi:10.1210/me.10.12.1582)
Dehm SM & Tindall DJ 2007 Androgen receptor structural and
functional elements: role and regulation in prostate cancer. Molecular
Endocrinology 21 2855–2863. (doi:10.1210/me.2007-0223)
Denayer S, Helsen C, Thorrez L, Haelens A & Claessens F 2010 The rules of
DNA recognition by the androgen receptor. Molecular Endocrinology 24
898–913. (doi:10.1210/me.2009-0310)
Devos A, Claessens F, Alen P, Winderickx J, Heyns W, Rombauts W &
Peeters B 1997 Identification of a functional androgen-response
element in the exon 1-coding sequence of the cystatin-related
protein gene crp2. Molecular Endocrinology 11 1033–1043. (doi:10.1210/
me.11.8.1033)
Feldman BJ & Feldman D 2001 The development of androgen-independent
prostate cancer. Nature Reviews. Cancer 1 34–45. (doi:10.1038/
35094009)
Gregory CW, He B, Johnson RT, Ford OH, Mohler JL, French FS &
Wilson EM 2001 A mechanism for androgen receptor-mediated
prostate cancer recurrence after androgen deprivation therapy.
Cancer Research 61 4315–4319.
Haelens A, Verrijdt G, Schoenmakers E, Alen P, Peeters B, Rombauts W &
Claessens F 1999 The first exon of the human sc gene contains an
androgen responsive unit and an interferon regulatory factor element.
Molecular and Cellular Endocrinology 153 91–102. (doi:10.1016/S0303-
7207(99)00079-9)
Haelens A, Verrijdt G, Callewaert L, Peeters B, Rombauts W & Claessens F
2001 Androgen-receptor-specific DNA binding to an element in the
first exon of the human secretory component gene. Biochemical Journal
353 611–620. (doi:10.1042/0264-6021:3530611)
Ham J, Thomson A, Needham M, Webb P & Parker M 1988 Character-
ization of response elements for androgens, glucocorticoids and
progestins in mouse mammary tumour virus. Nucleic Acids Research 16
5263–5276.
Heemers HV & Tindall DJ 2007 Androgen receptor (AR) coregulators:
a diversity of functions converging on and regulating the AR
transcriptional complex. Endocrine Reviews 28 778–808. (doi:10.1210/
er.2007-0019)
Heinlein CA & Chang C 2004 Androgen receptor in prostate cancer.
Endocrine Reviews 25 276–308. (doi:10.1210/er.2002-0032)
Khan AP, Rajendiran TM, Ateeq B, Asangani IA, Athanikar JN, Yocum AK,
Mehra R, Siddiqui J, Palapattu G, Wei JT et al. 2013 The role of sarcosine
metabolism in prostate cancer progression. Neoplasia 15 491–501.
Lamont KR & Tindall DJ 2011 Minireview: alternative activation pathways
for the androgen receptor in prostate cancer. Molecular Endocrinology 25
897–907. (doi:10.1210/me.2010-0469)
Lee CM, Shih YP, Wu CH & Chen YM 2009 Characterization of the
5 0 regulatory region of the human glycine N-methyltransferase gene.
Gene 443 151–157. (doi:10.1016/j.gene.2009.05.001)
Lee CM, Yen CH, Tzeng TY, Huang YZ, Chou KH, Chang TJ & Chen YM
2013 Androgen response element of the glycine N-methyltransferase
gene is located in the coding region of its first exon. Bioscience Reports
33 (5) art:e00070. (doi:10.1042/BSR20130030)http://jme.endocrinology-journals.org
DOI: 10.1530/JME-13-0169
 2013 The authors
Printed in Great BritainLin B, Wang J, Hong X, Yan X, Hwang D, Cho JH, Yi D, Utleg AG, Fang X,
Schones DE et al. 2009 Integrated expression profiling and ChIP-seq
analyses of the growth inhibition response program of the androgen
receptor. PLoS ONE 4 e6589. (doi:10.1371/journal.pone.0006589)
Lu NZ, Wardell SE, Burnstein KL, Defranco D, Fuller PJ, Giguere V,
Hochberg RB, McKay L, Renoir JM, Weigel NL et al. 2006 International
Union of Pharmacology. LXV. The pharmacology and classification
of the nuclear receptor superfamily: glucocorticoid, mineralocorticoid,
progesterone, and androgen receptors. Pharmacological Reviews 58
782–797. (doi:10.1124/pr.58.4.9)
Luke MC & Coffey DS 1994 Human androgen receptor binding to the
androgen response element of prostate specific antigen. Journal of
Andrology 15 41–51. (doi:10.1002/j.1939-4640.1994.tb01682.x)
Lund SD, Gallagher PM, Wang B, Porter SC & Ganschow RE 1991 Androgen
responsiveness of the murine beta-glucuronidase gene is associated
with nuclease hypersensitivity, protein binding, and haplotype-specific
sequence diversity within intron 9. Molecular and Cellular Biology 11
5426–5434.
Massie CE, Adryan B, Barbosa-Morais NL, Lynch AG, Tran MG, Neal DE &
Mills IG 2007 New androgen receptor genomic targets show an
interaction with the ETS1 transcription factor. EMBO Reports 8 871–878.
(doi:10.1038/sj.embor.7401046)
Massie CE, Lynch A, Ramos-Montoya A, Boren J, Stark R, Fazli L, Warren A,
Scott H, Madhu B, Sharma N et al. 2011 The androgen
receptor fuels prostate cancer by regulating central metabolism
and biosynthesis. EMBO Journal 30 2719–2733. (doi:10.1038/emboj.
2011.158)
Ngan S, Stronach EA, Photiou A, Waxman J, Ali S & Buluwela L 2009
Microarray coupled to quantitative RT-PCR analysis of androgen-
regulated genes in human LNCaP prostate cancer cells. Oncogene 28
2051–2063. (doi:10.1038/onc.2009.68)
Nirde P, Georget V, Terouanne B, Galifer RB, Belon C & Sultan C 1998
Quantitation of androgen receptor messenger RNA from genital skin
fibroblasts by reverse transcription – competitive polymerase chain
reaction. Journal of Steroid Biochemistry and Molecular Biology 66 35–43.
(doi:10.1016/S0960-0760(98)00006-5)
Ogawa H, Gomi T & Fujioka M 1993 Mammalian glycine N-methyl-
transferases. Comparative kinetic and structural properties of the
enzymes from human, rat, rabbit and pig livers. Comparative
Biochemistry and Physiology, Part B 106 601–611. (doi:10.1016/
0305-0491(93)90137-T)
Ogawa H, Gomi T, Takusagawa F & Fujioka M 1998 Structure, function and
physiological role of glycine N-methyltransferase. International
Journal of Biochemistry & Cell Biology 30 13–26. (doi:10.1016/S1357-
2725(97)00105-2)
Ovcharenko I, Loots GG, Giardine BM, Hou M, Ma J, Hardison RC, Stubbs L
& Miller W 2005 Mulan: multiple-sequence local alignment and
visualization for studying function and evolution. Genome Research 15
184–194. (doi:10.1101/gr.3007205)
Reddy TE, Pauli F, Sprouse RO, Neff NF, Newberry KM, Garabedian MJ &
Myers RM 2009 Genomic determination of the glucocorticoid response
reveals unexpected mechanisms of gene regulation.Genome Research 19
2163–2171. (doi:10.1101/gr.097022.109)
Rennie PS, Bruchovsky N, Leco KJ, Sheppard PC, McQueen SA, Cheng H,
Snoek R, Hamel A, Bock ME, MacDonald BS et al. 1993 Characterization
of two cis-acting DNA elements involved in the androgen regulation
of the probasin gene. Molecular Endocrinology 7 23–36. (doi:10.1210/
me.7.1.23)
Rowling MJ & Schalinske KL 2003 Retinoic acid and glucocorticoid
treatment induce hepatic glycine N-methyltransferase and lower
plasma homocysteine concentrations in rats and rat hepatoma cells.
Journal of Nutrition 133 3392–3398.
Shang Y, Myers M & Brown M 2002 Formation of the androgen receptor
transcription complex. Molecular Cell 9 601–610. (doi:10.1016/S1097-
2765(02)00471-9)Published by Bioscientifica Ltd
Jo
u
rn
a
l
o
f
M
o
le
cu
la
r
E
n
d
o
cr
in
o
lo
g
y
Research S OTTAVIANI and others Androgen regulation of GNMT 51 :3 312Shen MM & Abate-Shen C 2010 Molecular genetics of prostate cancer: new
prospects for old challenges. Genes and Development 24 1967–2000.
(doi:10.1101/gad.1965810)
Song YH, Shiota M, Kuroiwa K, Naito S & Oda Y 2011 The important role
of glycine N-methyltransferase in the carcinogenesis and progression
of prostate cancer. Modern Pathology 24 1272–1280. (doi:10.1038/
modpathol.2011.76)
Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B,
Mehra R, Lonigro RJ, Li Y et al. 2009 Metabolomic profiles delineate
potential role for sarcosine in prostate cancer progression. Nature 457
910–914. (doi:10.1038/nature07762)
Verrijdt G, Schauwaers K, Haelens A, Rombauts W & Claessens F 2002
Functional interplay between two response elements with distinct
binding characteristics dictates androgen specificity of the mouse
sex-limited protein enhancer. Journal of Biological Chemistry 277
35191–35201. (doi:10.1074/jbc.M205928200)
Verrijdt G, Schoenmakers E, Alen P, Haelens A, Peeters B, Rombauts W
& Claessens F 1999 Androgen specificity of a response unithttp://jme.endocrinology-journals.org
DOI: 10.1530/JME-13-0169
 2013 The authors
Printed in Great Britainupstream of the human secretory component gene is mediated by
differential receptor binding to an essential androgen response
element. Molecular Endocrinology 13 1558–1570. (doi:10.1210/me.13.
9.1558)
Waltering KK, Helenius MA, Sahu B, Manni V, Linja MJ, Janne OA &
Visakorpi T 2009 Increased expression of androgen receptor
sensitizes prostate cancer cells to low levels of androgens.
Cancer Research 69 8141–8149. (doi:10.1158/0008-5472.CAN-
09-0919)
Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J, Chen Z, Beroukhim R,
Wang H, Lupien M et al. 2009 Androgen receptor regulates a distinct
transcription program in androgen-independent prostate cancer.
Cell 138 245–256. (doi:10.1016/j.cell.2009.04.056)
Yu J, Mani RS, Cao Q, Brenner CJ, Cao X, Wang X, Wu L, Li J,
Hu M, Gong Y et al. 2010 An integrated network of androgen
receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate
cancer progression. Cancer Cell 17 443–454. (doi:10.1016/j.ccr.2010.
03.018)Received in final form 22 August 2013
Accepted 29 August 2013
Accepted Preprint published online 30 August 2013Published by Bioscientifica Ltd
